Weekly FDA Drug Pipeline Calendar (April 24 - April 28)

The CEO of $CNS Pharmaceuticals (CNSP.US)$ has disclosed the acquisition of 15,000 shares at a mean price of $0.69 per share. Shares closed the week down 20% at $1.89.

$Dermata Therapeutics (DRMA.US)$ received FDA approval for its proposed protocols and regulations for the Phase 3 clinical trials of DMT310, its acne treatment. The company intends to launch the Phase 3 program during the latter half of 2023. Shares closed the week up 127% at $2.63.

In a joint statement this week, $GlaxoSmithKline (GSK.US)$ and $BELLUS Health (BLU.US)$ announced that GSK will purchase BELLUS, a Canadian-based biopharmaceutical firm that concentrates on enhancing the quality of life for individuals struggling with refractory chronic cough (RCC), at a cash price of $14.75 per share of Bellus. This acquisition will result in a total equity value of around $2 billion and is at an advanced stage. Shares closed the week up 103% at $14.43.

Tuesday, April 25, 2023
PDUFA PR $Ionis Pharmaceuticals (IONS.US)$ BIIB Tofersen - (VALOR)
PDUFA PF $Seres Therapeutics (MCRB.US)$ SER-109 - (ECOSPOR)
Consumer Confidence 10 am ET

Friday, April 28, 2023
PDUFA $Intelgenx Technologies Corp. (IGXT.US)$ Buprenorphine Buccal Film - (Belbuca Biosimilar)
Advisory Committee $AstraZeneca (AZN.US)$ $Merck & Co (MRK.US)$ LYNPARZA (olaparib) - (PROpel)
March Personal Spending and Personal Income 8:30 am ET